Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or South Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to South Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. South Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Suhail Kumar (NPI 1114104999)

Field	Value
Entity Type	Individual
Organization	Suhail Kumar
Address	50 International Dr Ste 325
City	Greenville
State	SC
ZIP	29615
Taxonomy	Rheumatology Physician
NPI Enumerated	January 24, 2008

Payer Source	Total Paid
Medicare	$3.4M
Medicaid	$0

Key Findings

This provider’s Medicare footprint is the dominant — and effectively sole — public-payor revenue stream: Total Medicare revenue is $3.4M while there is no Medicaid billing on file, making the practice functionally single‑payer (Medicare) for public programs and exposing the revenue mix to Medicare-specific reimbursement dynamics. The NPI was enumerated on 2008-01-24 (~18 years ago), indicating an established practice with a long operating history in the Greenville, SC market.

The Medicare revenue mix is highly concentrated in infused and injected biologic therapies: the precomputed top 3 Medicare codes account for 50.6% of total Medicare revenue, and the single largest code, J0129, contributed $638.6K (19.0% of Medicare revenue). This concentration signals that biologic drug administration is the primary service line driving revenue rather than routine office visits or diagnostic testing.

Line-of-service details reinforce a biologics/infusion-focused operation: the top codes are J0129 (abatacept), J0717 (certolizumab pegol), and J1602 (intravenous golimumab), and additional high-revenue drug codes on the list include J9312 (rituximab) and J1745 (infliximab). Together these drug administration codes — several of which are specialty biologics frequently used in rheumatology — point to a practice built around on-site infusion and parenteral biologic delivery rather than primarily procedural or imaging services.

The practice shows exceptionally high infusion throughput on chemotherapy/infusion administration codes: 96413 is listed as $93.7K (2.8% of Medicare revenue) and is flagged as an "extreme outlier, far above typical national volume" at the 99th percentile; other infusion-additive codes such as 96401 ($42.4K, 97th percentile) and 96415 ($8.5K, 98th percentile) are also notably above typical national volume. These signals together imply sustained, high-volume administration of infused therapies across multiple sessions per patient.

Competitive standing is mixed by code: the provider ranks notably high on several infusion drug codes — J1602 ranks #50 of 1041 (95th percentile; notably above typical national volume) and J1745 ranks #60 of 1352 (96th percentile; notably above typical national volume) — indicating regional/national strength in administering certain infused biologics. Other biologic codes like J0129 (rank #148 of 1221, 88th percentile) and J0717 (rank #71 of 848, 92nd percentile) fall into percentile bands described as typical or unremarkable volume, so leadership is concentrated in specific agents rather than across the entire biologic portfolio.

Clinical operations include routine E/M volume alongside infusion services: 99214 generated $63.6K (1.9% of Medicare revenue) and ranks #21029 of 479517 (96th percentile; notably above typical national volume), indicating a higher-than-typical number of moderate-complexity established-patient visits to support the infusion service line. At the same time, many low-revenue E/M and diagnostic codes appear at modest percentiles, underscoring that face-to-face visits support but do not dominate revenue compared with drug administration.

Service breadth shows some diversification within therapeutic infusions but limited non-infusible Medicaid exposure: the top revenue contributors are almost entirely injectable/infused drugs (J-series codes) with only small shares from laboratory and imaging codes such as 85025 and 77080, and there is no Medicaid billing on file. The absence of Medicaid claims suggests limited engagement with that payer population, which could affect referral patterns and access for Medicaid beneficiaries in the local market.

Tenure and operational implication: with approximately 18 years since NPI enumeration and a Medicare revenue base of $3.4M concentrated in high-cost biologics, the practice appears to be an established infusion-centered rheumatology operation that may be sensitive to changes in biologic reimbursement, drug acquisition costs, and Medicare policy updates affecting infusion coding and payment. Analysts should treat the provider as an infusion-heavy, Medicare-dependent entity when modeling payer-contracted revenue scenarios or assessing competitive capacity in Greenville, SC.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

30 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	19,350	$30	$638.5K
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	142,400	$1	$569.6K
J1602	Injection, golimumab, 1 mg, for intravenous use	48,700	$10	$487K
J9312	Injection, rituximab, 10 mg	7,260	$60	$464.6K
J1745	Injection, infliximab, excludes biosimilar, 10 mg	12,150	$30	$303.8K
J3262	Injection, tocilizumab, 1 mg	48,920	$10	$244.6K
J0490	Injection, belimumab, 10 mg	5,420	$40	$195.3K
J0897	Injection, denosumab, 1 mg	6,300	$20	$113.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	1,010	$90	$93.7K
J3111	Injection, romosozumab-aqqg, 1 mg	10,920	$10	$87.4K

Showing 1–10 of 30

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 30 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. South Carolina Distribution

Suhail Kumar — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — South Carolina

Full comparison — all codes billed, vs. state median

30 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0129	10	40	9,640	$30	$424.2K
J0717	3	20	59,200	$1	$278.4K
J1602	3	40	23,560	$10	$264.5K
J3262	10	20	40,900	$1	$202.7K
J9312	1	20	2,340	$60	$193.7K
J0490	2	10	4,820	$40	$152K
J3111	24	40	12,390	$10	$129.4K
J1745	3	50	3,250	$30	$107K
J0897	52	250	2,400	$20	$91.2K
99214	717	7,860	160	$80	$23.2K

Showing 1–10 of 30

Related Providers

Other providers that share a Tax Identification Number (TIN) with Suhail Kumar, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Richard Kim	SC	Rheumatology Physician	$3.6M	$0
Long Huynh-duc	SC	Rheumatology Physician	$3.2M	$0
Corey Ephrussi	SC	Rheumatology Physician	$1.8M	$1.2K

Nearby Providers

Other providers in the same ZIP code as Suhail Kumar, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Childrens Medical Center	SC	Specialist	$0	$17.1M
Prisma Health University Medical Group	SC	Developmental - Behavioral Pediatrics Physician	$0	$16M
Agapi Behavioral Consultants	SC	Behavior Analyst	$0	$15M
St Francis Hospital, Inc.	SC	General Acute Care Hospital	$0	$13M
Eastside Pediatric Dentistry PA	SC	Pediatric Dentistry	$0	$10M
Magnolia Medical Group Inc	SC	Physical Therapist	$0	$9.9M
Greenville Health Corporation	SC	Durable Medical Equipment & Medical Supplies	$0	$8.9M
D&s Community Services Sc, LLC	SC	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$8.3M
Bloom Behavioral Therapy LLC	SC	Mental Health Counselor	$0	$7.5M
Prisma Health-upstate	SC	General Acute Care Hospital	$0	$6.4M

Suhail Kumar — Billing Profile & Reimbursement Data

Sign up for Suhail Kumar — Billing Profile & Reimbursement Data policy alerts

Suhail Kumar — Billing Profile & Reimbursement Data

Sign up for Suhail Kumar — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References